<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609307</url>
  </required_header>
  <id_info>
    <org_study_id>96301</org_study_id>
    <nct_id>NCT03609307</nct_id>
  </id_info>
  <brief_title>Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial</brief_title>
  <official_title>Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the effect of combined intravitreal Bevacizumab and
      Propranolol injection versus Bevacizumab monotherapy in patients with Age Related Macular
      Degeneration.

      Methods:

      In this study patients with Age Related Macular Degeneration who are na√Øve or had history of
      previous treatment are included. The eligible patients in randomized in two groups
      &quot;Bevacizumab&quot; and &quot;Bavacizumab + propranolol&quot; and in injected intravitreally for 3 times
      monthly. In &quot;Bevacizumab+propranolol&quot; group patients receive two injections at each session
      Bavacizumab and propranolol. In &quot;Bevacizumab&quot; group patients receive only Bevacizumab. The
      patients are followed for 6 months and central macular thickness and visual acuity is
      measured at baseline and monthly for 6 month. Baseline ancillary exams include Fluorescein
      Angiography and OCT-Angiography which is performed at the final exam as well. Patients
      needing any therapeutic intervention is addressed during the 6 month follow up period.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular Thickness</measure>
    <time_frame>1 month</time_frame>
    <description>Spectral Domain Optical Coherence Tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 month</time_frame>
    <description>Early Treatment Diabetic Retinopathy Study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>injection Combined Intravitreal bevacizumab and propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receive two injections at each session Bavacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>injection Intravitreal bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receive only Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined Intravitreal bevacizumab and propranolol</intervention_name>
    <description>these patients receive two injections at each session Bavacizumab and propranolol</description>
    <arm_group_label>injection Combined Intravitreal bevacizumab and propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal bevacizumab</intervention_name>
    <description>these patients receive only Bevacizumab</description>
    <arm_group_label>injection Intravitreal bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Wet AMD and Vision less than 20/40

        Exclusion Criteria:

          -  History of cardiac ,renal, respiratory diseases (due to beta blocker toxicity),

          -  Associated with other Macular abnormalities such as Diabetic Retinopathy, Macular
             traction

          -  History of ocular inflammation

          -  Subretinal fibrosis

          -  History of Cataract surgey less than 6 months

          -  History of Glaucoma Surgery ,Vitreoretinal surgery

          -  Media opacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ramin Noorinia, MD</last_name>
    <phone>009822591616</phone>
    <email>labbafi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ophthalmic Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramin Noorinia, MD</last_name>
      <phone>009822591616</phone>
      <email>labbafi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>July 25, 2018</last_update_submitted>
  <last_update_submitted_qc>July 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

